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Abstract
The major etiological factor for cervical cancer is the high-risk human papillomavirus (HPV),
which encodes E6 and E7 oncogenes. However, HPV is not sufficient and estrogen has been
proposed as an etiological cofactor for the disease. Its requirement has been demonstrated in
mouse models for HPV-associated cervical cancer (e.g., K14E7 transgenic mice). Although
germline knockout of estrogen receptor alpha (ERα) renders mice resistant to cervical cancer, the
cell type-specific requirement for ERα is not known. In this study, we demonstrate that temporal
deletion of stromal ERα induced complete regression of cervical dysplasia in K14E7 mice. Our
results strongly support the hypothesis that stromal ERα is necessary for HPV-induced cervical
carcinogenesis and implicate paracrine mechanisms involving ERα signaling in the development
of estrogen-dependent cervical cancers. This is the first evidence to support the importance of
stromal ERα in estrogen-dependent neoplastic disease of the female reproductive tract.
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Introduction
Cervical cancer is the second most frequent cancer and the second leading cause of death by
cancer in women worldwide [1, 2]. The vast majority of cervical cancer is associated with
specific types of human papillomavirus (HPV), the so-called high-risk HPVs. Specifically,
the high-risk HPV16 and HPV18 genotypes are found in approximately 60% and 20% of all
cervical cancers, respectively [3]. The tumorigenic potential of these viruses stems mainly
from two viral oncogenes, E6 and E7, which are best known for their ability to inactivate
p53 and pRb tumor suppressor protein, respectively [2-4]. These oncogenes are necessary
for the progression of cervical disease (CIN1, CIN2, CIN3, invasive cancer) and the
continued growth of cervical cancer. It is estimated that approximately 75% of sexually
active women are infected with HPVs, yet only a minor fraction of such women develops
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cervical cancer [5]. This observation has suggested that HPV infection alone is not sufficient
for cervical cancer and that other cofactors are also necessary. Long-term use of oral
contraceptives (OCs) or high parity is associated with higher risk for cervical cancer in
HPV-infected women [6, 7]. These results implicate estrogen and/or progesterone in HPV-
induced cervical cancer because they are the factors common to both variables (OCs and
pregnancy). Complications in looking at a specific association of estrogen in human cervical
cancer are discussed in a recent review [8] and the role of estrogen in human cervical cancer
therefore remains unclear.
An essential role of estrogen in cervical cancer, however, has been clearly defined in HPV
transgenic mouse models. HPV16 transgenic mice express the E6 (K14E6), E7 (K14E7), or
both (K14E6/K14E7) oncogenes under the control of human keratin 14 (K14) promoter,
which drives transgene expression in stratified squamous epithelia, the natural host cell type
for HPV infection. An HPV oncogene in conjunction with physiologic levels of exogenous
estrogen promotes the development of cervical cancer, whereas either one of the two factors
alone does not [9-12]. Using this validated hormone/oncogene co-dependence mouse model,
we previously determined that estrogen receptor α (ERα) is necessary for estrogen to
cooperate with HPV in the development and continued growth of cervical cancer [13, 14].
Stromal cells play a pivotal role in development. For example, recombination of uterine
stroma with vaginal epithelium results in the development of uterine epithelium in vivo [15].
More recently, an in vivo uterine epithelial specific ERα knockout shows estrogen-induced
proliferation dependent on uterine stroma [16]. Stromal microenvironment also contributes
to the development of carcinomas. For instance, cancer cell-derived TGF-β promotes
transdifferentiation of fibroblasts to myofibroblasts, which in turn support and/or promote
cancer cell invasion and metastasis [17]. Stromal p53 mutation is associated with nodal
metastasis in sporadic breast cancers [18] and deletion of the APC tumor suppressor in the
stroma promotes the development of endometrial cancer in mice [19]. Such signaling
pathways in stroma that support carcinogenesis are attractive targets for cancer therapy.
ERα is crucial for the estrogenic responses (e.g., epithelial cell proliferation) of hormone-
responsive tissues such as mammary glands and female reproductive tracts [20]. It is also
critical for various cancers including breast cancer [21]. Although a role of stromal ERα in
tissue homeostasis and organogenesis has been extensively evaluated [16, 22, 23], it is
poorly understood in the context of cancer. In the present study, we utilized conditional ERα
knockout (ERαf/f) mice to assess whether stromal ERα is important for cervical
carcinogenesis in the K14E7 transgenic mouse model. Our results show for the first time
that ERα expressed in stromal cells is required for estrogen-dependent cervical cancer in the
HPV transgenic mouse model.
Materials and Methods
Mice and treatments
K14E7 transgenic mice and conditional ERα knockout (ERαf/f) mice were described
previously [24, 25]. CAGGCre-ER™ (referred to as CMVCreER herein) transgenic mouse
was purchased from the Jackson Laboratory [26]. This mouse was generated to drive
expression of tamoxifen-inducible cre recombinase ubiquitously in all tissues and cell types.
Experimental mice were generated by crossing K14E7/ERαf/f and CMVCreER/ERαf/f,
which were obtained by intercrossing F1 generations of K14E7 (FVB) and ERαf/f (albino
C57BL/6) mating and CMVCreER (C57BL/6 × CBA × SWR) and ERαf/f mating,
respectively. Female progenies were genotyped by PCR. A slow-releasing 17β-estradiol
tablet (0.05 mg/60 days) (Innovative Research of America, Sarasota, FL) was inserted
subcutaneously under the dorsal skin every two months beginning at 4-6 weeks of age.
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Groups of mice were injected intraperitoneally (i.p.) with tamoxifen (4 mg/day) for 5 days
after 6-month estrogen treatment to activate cre [26]. Mice were injected i.p. with 0.3 ml of
bromo-deoxyuridine (BrdU) (12.5 mg/ml) 1 hr prior to euthanasia to measure cellular
proliferation. All procedures were carried out according to an animal protocol approved by
the University of Wisconsin Medical School Institutional Animal Care and Use Committee.
Tissue processing and histological analyses
Female reproductive tracts were fixed in 4% paraformaldehyde (PFA) and embedded in
paraffin. Serial sections were made throughout cervices at 5-μm thickness. Every tenth slide
was stained with hematoxylin and eosin (H&E) and the worst disease in each mouse was
determined as described previously [11].
Immunohistochemistry
Antibodies were purchased from Santa Cruz [PR (H190) and ERα (MC20)], Calbiochem
(BrdU), Rockland (biotinylated anti-rabbit/mouse IgG), Invitrogen (anti-rabbit IgG
conjugated with Alexa 488). Immunohistochemical stainings for PR, ERα and BrdU were
performed as described previously [13, 27, 28].
Statistical analyses
Two-sided Fisher's exact test and Wilcoxon rank sum test were carried out with MSTAT
software version 5.41. Fisher's exact test was used for cancer incidence and number of
disease-free mice, and Wilcoxon rank sum test for disease severity and number of ERα+ or
BrdU+ cells.
Results
Tamoxifen treatment induces deletion of ERα in the cervical stroma but not in the
epithelium of CMVCreER/ERαf/f mice
The initial goal of this study was to evaluate the temporal requirements for ERα in all cells
within the cervix during different stages in cervical carcinogenesis. To accomplish this we
made use of the ERαf/f mice carrying a conditional (floxed) allele of ERα, crossed to the
CMVCreER mice which were chosen because they were expected to drive Cre expression
ubiquitously in all tissues and cell types of the mouse reproductive tract and other organs.
We tested various tamoxifen treatment regimens (daily i.p. injections, 0.5, 1, 2, 3, 4, 5 mg/
day for 1, 3, or 5 days) based on prior studies [26, 29]. The effect of each dosing schedule
was initially evaluated by monitoring for gross changes in the reproductive tracts and
measuring their wet weight after 2 weeks of the first dose. We observed that treatment with
4 mg of tamoxifen for 5 days resulted in most dramatic morphological changes without
morbidity (Fig. 1a). Tamoxifen-treated mice had hemorrhagic ovaries and atrophic
reproductive tracts, which is reminiscent of ERα knockout mice [30]. Although treatment
with 5 mg of tamoxifen for 3 days resulted in similar effects in surviving animals, this dose
incurred morbidity and mortality in 2 of 5 mice (40%). We also evaluated ERα expression
by immunohistochemistry (IHC). To our surprise, ERα expression was not affected in the
cervical epithelium, yet absent in the cervical stroma (Fig. 1b, top panel). In contrast, ERα
expression was abrogated in both epithelium and stroma of the uterus (Fig. 1b, bottom
panel). We did not observe epithelial ERα deletion in cervices of CMVCreER/ERαf/f mice
treated with 4 mg of tamoxifen for 1, 3, or 5 days and sacrificed 24 hours after the final
injection (Online Resource 1). ERα expression was also retained in the cervical epithelium
of K14Cre/ERαf/f mice of which ovaries are removed (Online Resource 1), despite the fact
1http://www.mcardle.wisc.edu/mstat
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that K14Cre efficiently deletes other floxed genes in the cervical epithelia [31, 32]. This
raises the possibility that the floxed ERα allele in cervical epithelial cells is resistant to cre-
mediated recombination. Regardless of why the ERα allele was not deleted in the cervical
epithelia, this fact provided us the opportunity to evaluate the individual role of stromal ERα
in cervical carcinogenesis.
Cervical disease is absent in CMVCreER/K14E7/ERαf/f mice treated with tamoxifen for 5
days
To address whether stromal ERα is crucial for cervical carcinogenesis in the mouse model
we generated CMVCreER/K14E7/ERαf/f and K14E7/ERαf/f mice, and each genotype was
divided into three treatment groups (Fig. 2a). Female reproductive tracts were harvested
after treatment with 17β-estradiol (E2) for 6 months (6mE2 group), which is sufficient to
promote cervical cancer in K14E7 mice at varying penetrance depending on experimental
conditions and genetic background [11, 13, 32, 33]. The other groups were further treated
with E2 for 2 more months and given oil vehicle [8mE2 (-Tam) group] or tamoxifen [8mE2
(+Tam) group] for 5 days at 6-month-treatment with E2. These treatment regimens were
designed to evaluate importance of stromal ERα in continued growth of cervical cancer and
progression of CIN to invasive cancer. Female reproductive tracts were isolated at each end
point as depicted in Fig. 2a. Each mouse was histopathologically evaluated for the worst
cervical and vaginal disease as previously described (ERα-dependent vaginal cancer also
arises in our mouse model)[10, 13].
The vast majority of K14E7/ERαf/f 6mE2 (14 of 14) and CMVCreER/K14E7/ERαf/f 6mE2
(12 of 14) mice had high-grade dysplasia, CIN2/3, indicative of neoplastic progression,
though none had developed cervical cancer (Table 1). This was surprising because E2
treatment for 6 months is sufficient to promote cervical cancers in the majority of K14E7
transgenic mice on FVB background [11, 32]. By 8- month E2 treatment cervical cancers
were beginning to arise in both the K14E7/ERαf/f and CMVCreER/K14E7/ERαf/f mice
(Table 1). Considering that mice used in this study are on a mixed genetic background from
4 strains, these data indicate that the rate of progression of cervical carcinogenesis likely
depends on the genetic background of mice. The high penetrance of high-grade dysplasia at
the 6-month E2 treatment endpoint did provide us the ability to ask what is the importance
of stromal ERα in this stage of cervical neoplasia. That the overall disease severity (p =
0.07) and number of cervical disease-free mice (p = 0.48) were not significantly different
between the K14E7/ERαf/f 6mE2 and CMVCreER/K14E7/ERαf/f 6mE2 (not treated with
tamoxifen) confirmed that CMVCreER transgene itself had no influence on cervical
carcinogenesis. As mentioned before, cervical cancers were observed when both genotypes
were treated with E2 for 8 months [2 of 15 K14E7/ERαf/f 8mE2 (-Tam) mice and 1 of 4
CMVCreER/K14E7/ERαf/f 8mE2 (-Tam) mice]. Overall disease severity in CMVCreER/
K14E7/ERαf/f 8mE2 (-Tam) and K14E7/ERαf/f 8mE2 (-Tam) was similar (p = 0.29),
confirming no significant effect of CMVCreER transgene in the absence of tamoxifen
treatment. Consistently, cervical epithelia of K14E7/ERαf/f 8mE2 (-Tam) and CMVCreER/
K14E7/ERαf/f 8mE2 (-Tam) were histologically indistinguishable (Fig. 2b, panels i & ii).
Next we compared cervical disease phenotypes between K14E7/ERαf/f 8mE2 (-Tam) and
K14E7/ERαf/f 8mE2 (+Tam). The number of cervical disease-free mice (p = 0.11) and
overall disease severity (p = 0.06) were not significantly different between these two control
groups (Table 1). Their epithelia also were similar to each other at the histological level
(Fig. 2b, panels i & iii). These control comparisons indicate that the 5-day-long tamoxifen
treatment itself has no significant effect on cervical carcinogenesis in our mouse model.
Strikingly, only 2 of 18 (11.1%) CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice had CIN3
and the rest were disease-free, whereas 14 of 18 K14E7/ERαf/f 8mE2 (+Tam) mice had
CIN3 or cervical cancer (Table 1). Differences in the overall disease severity (p = 3.7 ×
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10-5) and the frequency of disease-free mice (p = 1.3 × 10-4) between the two groups were
highly significant. The cervical epithelia of CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice
were hypoplastic compared to those of K14E7/ERαf/f 8mE2 (+Tam) mice (Fig. 2b, panels
iii & iv). Similar differences in disease phenotypes between these two groups were observed
in vaginal tissues (Table 1).
Cervical disease states correlate with ERα status in the cervical stroma
In order to confirm that the absence of cervical disease in CMVCreER/K14E7/ERαf/f 8mE2
(+Tam) mice was due to lack of ERα expression in the stroma, we evaluated cervical tissues
for ERα expression by IHC. As expected, ERα expression was readily detected in stroma
and epithelia of K14E7/ERαf/f 8mE2 (-Tam), K14E7/ERαf/f 8mE2 (+Tam), and
CMVCreER/K14E7/ERαf/f 8mE2 (-Tam) mice (Fig. 3a, panels i-iii). In contrast and similar
to that shown in Fig. 1b, ERα-positive stromal cells were rarely found in CMVCreER/
K14E7/ERαf/f 8mE2 (+Tam) mice, while ERα expression in the epithelia remained highly
penetrant (Fig. 3a, panel iv). Quantitative analyses showed that only 1.2% of cervical
stromal cells in disease-free CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice expressed
ERα, whereas 77.2% in K14E7/ERαf/f 8mE2 (+Tam) mice did (Fig. 3b). This difference
was highly significant (p = 0.005). We also investigated ERα status in the cervices of two
CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice that had CIN3 (see Table 1). We found that
79.0% of cervical stromal cells expressed ERα (Figs. 3b & c), which is comparable to
K14E7/ERαf/f 8mE2 (+Tam) mice (compare Fig. 3a, panel iii and Fig. 3c; p = 0.22). It is
unclear why tamoxifen treatment was not efficient in activating cre activity in these two
mice. Nonetheless, these results point further to the correlation between the retention of
cervical neoplastic disease and ERα expression in the stroma. Female reproductive tracts
were isolated from a subset of CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice a day after
tamoxifen treatment for 3 or 5 days to confirm the absence of ERα deletion in cervical
epithelia. While stromal ERα was deleted, expression of epithelial ERα was not affected
(Fig. 3d), further supporting that absence of cervical diseases is due to loss of ERα in the
stroma but not in the epithelium. Expression of progesterone receptor (PR) in the epithelium
and stroma of female lower reproductive tracts is dependent upon ERα in the epithelium and
stroma, respectively [15, 27]. We found that PR was expressed in cervical epithelial cells in
CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice as well as K14E7/ERαf/f 8mE2 (+Tam)
mice (Fig. 3e). In contrast, PR expression was barely detectable in the ERα-deleted cervical
stroma of the CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice, unlike ERα-intact stroma of
K14E7/ERαf/f 8mE2 (+Tam) mice. This result indicates that ERα is functional specifically
in the epithelium, but not the stroma of CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice.
Taken together, we conclude that stromal ERα is necessary for cervical carcinogenesis in
HPV transgenic mouse model.
Deletion of stromal ERα abrogates cell proliferation in the cervical epithelia
We also investigated if estrogen-dependent epithelial cell proliferation in the cervices of
CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice was compromised. We found that
proliferation indices of K14E7/ERαf/f 8mE2 (-Tam), K14E7/ERαf/f 8mE2 (+Tam), and
CMVCreER/K14E7/ERαf/f 8mE2 (-Tam) were similar in both basal (13.8~15.2%) and
suprabasal layer (5.7~6.1%) of the cervical epithelia (Figs. 4a & b). These results
demonstrate that tamoxifen or CMVCreER transgene, individually, had no effect on cervical
epithelial cell proliferation, consistent with cervical disease phenotypes shown in Table 1. In
contrast, proliferation indices of basal and suprabasal layer of the cervical epithelia of
CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice were 1.6% and 0.1%, respectively (Figs. 4a
& b). These proliferation indices were significantly lower than that observed in K14E7/
ERαf/f 8mE2 (+Tam) mice (p = 0.03) demonstrating that stromal ERα is necessary for
proliferation of basal and suprabasal cells in the cervical epithelium.
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Discussion
ERα plays a pivotal role in the development of various cancers including, but not limited to,
breast cancers [20]. Estrogen cooperates with HPV oncogenes in a mouse model for HPV-
associated cervical cancer [10-12, 34]; and ERα is required for this synergistic effect of
estrogen and HPV oncogenes [13]. In this study, we investigated cell-type specific
requirement of ERα in HPV-mediated cervical carcinogenesis, and learned that deletion of
ERα in cervical stroma results in regression of CIN3 and dramatic reduction in cervical
epithelial cell proliferation in K14E7 transgenic mice (Table 1 & Figs. 3 & 4). Epithelial
ERα was intact immediately after tamoxifen treatment and was functional as demonstrated
by expression of PR in cervical epithelium of CMVCreER/K14E7/ERαf/f 8mE2 (+Tam)
mice (Fig. 3e). These results indicate that epithelial ERα is not sufficient and stromal ERα
is necessary for cervical carcinogenesis. These findings provide direct evidence that a
paracrine mechanism mediated by stromal ERα is necessary for the maintenance of
neoplastic state in the mouse cervix. It is, however, unclear if stromal ERα is required for
continued growth of cervical cancer as well because we did not observe frank cancer in the
control mice (CMVCreER/K14E7/ERαf/f 6mE2). Nonetheless, this is the first study to show
the requirement of stromal ERα for estrogen-dependent cervical carcinogenesis in vivo.
This finding is consistent with prior observations that ERα expression is retained in the
stroma surrounding cervical cancer in women [35, 36]. Most breast cancer cells require ERα
for continued growth and epithelial ERα is required for proliferation of mammary epithelial
cells in mice [37]. Although a role of stromal ERα in the development of ERα-positive
breast cancer has not been elucidated, ERα expressed in Tie2-positive stromal cells (e.g.,
endothelial cells) promotes growth of ERα-negative cancers by mediating adaptation of
tumor angiogenesis [38]. ERα expressed in prostate stromal cells promotes expression of
MMP2 via induction of TGFβ1, which enhances invasion of prostate cancer cells into
Matrigel in vitro [39]. These results support the idea that stromal ERα may exert distinct
functions depending on cancers.
A model for roles of ERα in cervical carcinogenesis
Although HPV oncogenes (i.e., E6 and E7) are necessary for continued growth of cervical
cancer cells [40, 41], their ability to promote cell proliferation is largely restricted to the
suprabasal layer of the murine cervical epithelium [12, 33]. However, this latter activity is
severely compromised when expression of wt ERα is abolished in the whole reproductive
tract [13]. ERα is known to induce proliferation in basal layer of the cervical epithelium but
not in suprabasal layer [13]. We learned in this study that stromal ERα is necessary for the
proliferation of both the basal and suprabasal cells within the cervical epithelium of K14E7
mice (Fig. 4). These results are similar to prior findings showing a requirement of stromal
ERα for physiologic proliferation of uterine columnar and vaginal squamous epithelial cells
in response to estrogen [16, 22, 42]. Based on our and others’ studies, we propose that
stromal ERα provides a major mitogenic signal for basal cells in the cervical epithelium,
which in turn supports suprabasal cell proliferation induced by HPV. HPV also inhibits
apoptosis and induces chromosomal instability, which is known to promote cancers [4, 11,
43]. It has been proposed that epithelial ERα may also play a role in cervical carcinogenesis.
Estrogen activates HPV promoter that drives E6/E7 expression in the cervical epithelium of
HPV18URR-lacZ transgenic mice [44]. Enhanced expression of E6 and E7 provides
selective growth advantage to cells [45]. We predict that ERα is responsible for this
regulation because ERα is not detectable in the cervix [13] and HPV genome contains
putative estrogen responsive elements (EREs), ERα binding sites [46]. A negative role of
epithelial ERα has been also demonstrated. ERα expressed in cervical cancer cells or
dysplastic cells inhibits their ability to invade chick chorioallantoic membrane [47], which is
consistent with the observation that ERα inhibits migration and invasion of breast cancer
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cells [48-50]. It is plausible that epithelial ERα plays a positive role in early stages of
carcinogenesis (i.e., development of CIN) and a preventive role in later stages (i.e.,
progression to invasive cancer and metastasis).
If this model were true, one would predict that deletion of ERα in cervical epithelia will
enhance invasion of dysplastic cells, thereby increasing cancer burden in the context of our
mouse model in which HPV oncogenes are under the control of K14 promoter unresponsive
to estrogen [51]. Experiments to test this possibility were hampered by our inability to delete
ERα in cervical epithelia (Online Resource 1 and Figs. 1 & 3). Use of K14Cre transgenic
mice was also unsuccessful to induce efficient deletion of ERα in cervical epithelium even
when ovaries were removed to block a potential selective pressure against ERα-deleted cells
provided by estrogen (Online Resource 1). K14Cre transgenic mice have been used
successfully to delete other floxed alleles (e.g., p53, pRb) in cervical epithelium [31, 32] and
the floxed ERα allele was readily deleted in cervical stroma and the whole uterus (Fig. 1). It
is possible that CMVCreER is less active in cervical epithelia than in cervical stroma or
whole uteri similar to mosaicism shown in Chx10 BAC transgenic mice [52, 53]. It is also
possible that the absence of recombination in the cervical epithelia in CMVCreER and
K14Cre mice reflects the fact that recombination efficiency varies depending on target
alleles [53, 54].
Potential ERα target genes in stromal cells that are crucial for cervical carcinogenesis
It will be challenging to identify ERα target genes in cervical stromal cells that are
necessary to support cervical carcinogenesis because (1) ERα is known to regulate (i.e.,
activation and repression) thousands of genes and (2) it is unclear if the same genes are
regulated by ERα when mice are treated with estrogen for hours compared to months (6
months in the case of our mouse model). However, the fact that paracrine factors induced by
ERα likely contribute to the development of neoplastic states (Table 1 & Fig. 3) narrows
down the list of candidate genes. Among them, insulin-like growth factor I (IGF-1),
keratinocyte growth factor (KGF), and Wnt ligands are of particular interest. IGF-1 is a
direct target of ERα and necessary for estrogen-induced cell proliferation in uterine
epithelium [55, 56] and higher serum levels of IGF-1 are associated with increased risk for
CIN [57]. KGF receptor is expressed in cervical cancer cell lines and cancer specimens [58].
In HPV16-immortalized human cervical epithelial cells, KGF promotes proliferation and
anchorage-independent growth as well as secretion of urokinase-type plasminogen activator
that is known associated with invasiveness of cancer cells [59, 60]. Inhibition of canonical
wnt signaling abrogates estrogen-dependent epithelial cell proliferation in mouse uterus and
wnt signaling is aberrantly activated in cervical cancer cell lines due to loss of Skt11
[61-63].
In summary, we demonstrate that deletion of stromal ERα promotes regression of cervical
neoplasia and abrogates epithelial cell proliferation in the cervix. These results provide an
incentive for the pursuit of studies investigating the role of stromal ERα in other estrogen-
dependent cancers and developing strategies to target stromal ERα to treat such cancers.
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Fig. 1.
Tamoxifen induces efficient deletion of ERα only in cervical stroma of CMVCreER/ERαf/f
mice. a Tamoxifen treatment induces atrophic female reproductive tracts in CMVCreER/
ERαf/f mice. ERαf/f (CMVCreER-, left) and CMVCreER/ERαf/f (CMVCreER +, right)
mice were i.p. injected with tamoxifen (4 mg/day for 5 days). The female reproductive tracts
were harvested two weeks after the first dose. Black and red arrowheads indicate ovaries and
hemorrhagic cysts, respectively. u, uterus; c, cervix; v, vagina. Scale bar, 5 mm. b ERα
expression is retained in the cervical epithelium of CMVCreER/ERαf/f mice treated with
tamoxifen. Mice were treated as in (a) and paraffin sections were stained for ERα (green).
DAPI-stained nuclei are pseudocolored red. Note that ERα is readily detected in cervical
epithelium (e) but not in cervical stroma (s) (upper panel) and both compartments of the
uterus (bottom panel) in CMVCreER/ERαf/f mice. Dotted lines indicate basement
membrane separating epithelium from stroma. Scale bar, 50 μm.
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Fig. 2.
Cervical disease is absent in CMVCreER/K14E7/ERαf/f mice treated with tamoxifen. a
Treatment regimen is depicted. E2 and Tam indicate estrogen and tamoxifen, respectively. b
Shown are high-magnification images of representative H&E-stained endocervical sections
from indicated groups of mice. Arrows point to atypia manifested as dark and enlarged
nuclei. Note that cervical intraepithelial neoplasia (CIN) is evident in K14E7/ERαf/f 8mE2(-
Tam), CMVCreER/K14E7/ERαf/f 8mE2 (-Tam), and K14E7/ERαf/f 8mE2 (+Tam) mice
(panels i-iii) but absent in CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice (panel iv). Scale
bar, 20 μm.
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Fig. 3.
Cervical disease states correlates with the ERα status in the cervical stroma. a ERα
expression is ablated in the cervical stroma of CMVCreER/K14E7/ERαf/f 8mE2 (+Tam)
mice without cervical disease. Paraffin sections of female reproductive tracts from indicated
groups of mice were stained for ERα (green). All diseased mice expressed ERα in both
epithelium and stroma of the cervix (panels i-iii), yet ERα was barely detectable in the
cervical stroma of disease-free CMVCreER/K14E7/ERαf/f 8mE2 (+Tam)mice (panel iv).
DAPI-stained nuclei are pseudocolored red. Scale bar, 20 μm. b Results shown in (a) and
(c) were quantified for number of ERα+ cells. At least 1000 cervical stromal cells in 4
random fields of each female reproductive tract were analyzed. Data are shown as mean ±
SEM. P value for two-sided Wilcoxon rank sum test is shown. c ERα expression is retained
in cervical stroma of CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice with CIN. Paraffin
sections from female reproductive tracts of the two mice that had cervical disease in the
CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) group were stained for ERα (green). DAPI-
stained nuclei are pseudocolored red. Scale bar, 20 μm. d Epithelial ERα is not deleted
shortly after tamoxifen treatment. Mice were treated with E2 for 6 months, treated with
tamoxifen (4mg) for 3 days (top panel) or 5 days (bottom panel), and sacrificed a day later.
Paraffin sections were subjected to ERα IHC (green). DAPI-stained nuclei are
pseudocolored red. Scale bar, 50 μm. e PR is expressed in the cervical epithelium of
CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice. Cervical tissues from indicated study
groups were subjected to PR IHC (brown nuclei). Nuclei were counterstained with
hematoxylin. Representative images from three mice in each group are shown. The black
lines point to basement membrane. Scale bar, 50 μm.
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Fig. 4.
Cervical epithelial cell proliferation is significantly reduced when ERα expression is ablated
in the stromal cells. a BrdU incorporation is reduced in the cervical epithelia of
CMVCreER/K14E7/ERαf/f 8mE2 (+Tam) mice. Paraffin sections from indicated study
groups were stained for BrdU to measure cell proliferation (brown nuclei). Nuclei were
counterstained with hematoxylin. Representative images from three mice for each group are
shown. Scale bar, 20 μm. b BrdU+ cells shown in (a) were quantified. Data are shown as
mean ± SEM (n = 3). P values for two-sided Wilcoxon rank sum test are shown.
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